BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA

被引：0
|
作者：
Djambazov, S. [1 ]
Slavchev, G. [1 ]
Velchev, M. [2 ]
Vekov, T. [3 ]
机构：
[1] HTA Ltd, Sofia, Bulgaria
[2] Pfizer Luxembourg SARL Branch Bulgaria, Sofia, Bulgaria
[3] Med Univ Pleven, Pleven, Bulgaria
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.135
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN57
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [41] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [42] COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY
    Altundag, K.
    Basaran, G.
    Oksuzoglu, B.
    Oven, B.
    Ozguroglu, M.
    Aydin, D.
    Hacibedel, B.
    Helvacioglu, K.
    Tuna, E.
    Tatar, M.
    VALUE IN HEALTH, 2016, 19 (03) : A146 - A146
  • [43] Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Mistry, Rohit
    Suri, Gaurav
    Young, Kate
    Hettle, Robert
    May, Jessica R.
    Brixner, Diana
    Oderda, Gary
    Biskupiak, Joseph
    Tang, Derek
    Bhattacharyya, Devarshi
    Bhattacharyya, Subrata
    Mishra, Dinesh
    Dalal, Anand A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (12) : 2143 - 2150
  • [44] Association of tumor DNA in circulation with clinical characteristics and treatment response in HR+/HER2-advanced breast cancer
    Solovieff, Nadia
    Su, Faye
    Leary, Rebecca
    Balbin, Alejandro
    Chakravartty, Arunava
    Lorenc, Karen Rodriguez
    Taran, Tetiana
    Babbar, Naveen
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [45] Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer
    Bardia, A.
    Modi, S.
    Oliveira, M.
    Campone, M.
    Ma, B.
    Dirix, L.
    Weise, A.
    Nardi, L.
    Zhang, V.
    Bhansali, S. G.
    Hewes, B.
    Chavez-MacGregor, M.
    CANCER RESEARCH, 2016, 76
  • [46] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
    Tolaney, S. M.
    Forero-Torres, A.
    Boni, V.
    Bachelot, T.
    Lu, Y-S
    Maur, M.
    Fasolo, A.
    Motta, M.
    Pan, C.
    Dobson, J.
    Hewes, B.
    Lee, S. Chin
    CANCER RESEARCH, 2017, 77
  • [47] Real-world treatment patterns for HER2+and HR+/HER2-advanced breast cancer in county areas of China
    Ji, Y.
    Qu, H.
    Zhou, F.
    Ren, Y.
    Liang, W.
    Wang, J.
    Dai, G.
    Liu, M.
    Luo, J.
    Wu, Q.
    Tan, X.
    Meng, Q.
    He, W.
    Liu, W.
    Hu, G.
    Wang, J.
    Tang, H.
    Gao, J.
    Liu, H.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1424 - S1425
  • [48] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S9 - S10
  • [49] A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2-advanced breast cancer patients with HER2 mutations
    Ma, Jing
    Li, Xuelu
    Zhang, Qianran
    Li, Ning
    Sun, Siwen
    Zhao, Shanshan
    Zhao, Zuowei
    Li, Man
    TRANSLATIONAL ONCOLOGY, 2022, 21
  • [50] Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2-Advanced/Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Tokuda, Toshiki
    Kaburagi, Takuji
    Okumura, Takehiro
    Karahashi, Tsuyoshi
    Nakajima, Kenichiro
    Higeta, Kaori
    Shimizu, Ken
    IN VIVO, 2019, 33 (06): : 2037 - 2044
12345